1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Date not available
Admin
News Article

ABM Therapeutics Announces US FDA Orphan Drug Designation to ABM-1310

ABM Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310, an innovative small molecule BRAF inhibitor. This designation is specifically intended for the treatment of individuals afflicted by glioblastoma (GBM) and who carry the BRAF V600 mutation. ABM-1310 is an orally administered medication with remarkable characteristics. It boasts high selectivity for BRAF mutations, excellent water solubility, and an ability to effectively permeate the blood-brain barrier. Currently, ABM-1310 is undergoing Phase I clinical trials at multiple medical sites across the United States and China. ABM-1310 has exhibited strong potential as an anticancer agent, while also demonstrating a favourable safety profile in patients with advanced BRAF V600 mutant solid tumours, including brain tumours like GBM and other gliomas. Promising results have emerged from the interim findings of the U.S. Phase I study. Glioblastoma (GBM) is exceptionally challenging and aggressive brain tumour to manage. Its intricate tumorigenesis and resistance to standard therapies contribute to the complexity of treatment. Conventional approaches like surgical resection, radiation, and chemotherapy have shown limited efficacy. With few treatment options available after the disease has progressed, the development of more effective treatments is in high demand.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!